Assessing HMB-002 for treating Von Willebrand Disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the safety, tolerability, pharmacokinetics, and pharmacodynamics of HMB-002 in adults with Type 1 Von Willebrand Disease. It consists of two parts: Part A involves a single ascending dose to establish initial safety and effects, while Part B focuses on the safety of repeat dosing and explores efficacy. The study is designed to gather critical data on how well HMB-002 works in this patient population.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Weight 50 to 120 kg, inclusive.
2. Documented diagnosis of Congenital VWD, confirmed by laboratory testing consistent with ISTH/ASH) diagnostic guidelines).
3. Vital signs are within normal ranges at Screening.
4. Participants must meet the following baseline organ function, indicated by laboratory criteria as Screening:

   1. Renal: Estimated glomerular filtration rate (eGFR) of ≥45 mL/min/1.73m\^2.
   2. Hepatic: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), and total bilirubin ≤1.5 upper limit of normal (ULN) at Screening. For participants with a history of Gilbert's Syndrome, total bilirubin ≤2 × ULN.
   3. Hematology \>85 g/L and platelet count \>120 x 10\^9/L.

   Part A Only:
5. Age: ≥18 and \<70 years of age at the time of informed consent.
6. VWD Subtype Eligibility:

   * Cohorts A1 and A2: Participants with Type 1 VWD, only.
   * Cohorts A3 and A4: Participants with Type 1 VWD (including Type 1C) and Type 2A VWD
7. Residual VWF activity of ≤ 50 IU/dL and FVIII activity ≤ 70 IU/dL during screening.

   Part B Only:
8. Age: ≥16 and \<70 years of age at the time of informed consent.
9. VWD Subtype Eligibility: Participants with Type 1 VWD (including Type 1C) and Type 2A.
10. Residual VWF activity of ≤50 IU/dL and FVIII activity ≤70 IU/dL during screening.
11. Symptomatic Disease: Participants must be symptomatic, typically reporting bleeding events on a monthly basis.
12. Bleeding History (must meet one of the following):

    1. Prior Observational Study Participation:

       The participant must have participated in the observational study HMB-002-101\_SCR (VELORA Discover), have a minimum annualized treated bleeding event (ATBR) of 3; OR
    2. Medical Record-Documented Bleeding History:

    The Investigator confirms that ≥3 treated bleeding events have been documented in the participant's medical record within the preceding 12 months.

    Part C Only:
13. Age: ≥18 and \<70 years of age at the time of informed consent.
14. Participants with Type 3 VWD or Type 1 VWD with low residual VWF and FVIII activity levels (VWF activity \<5 IU/dL and FVIII activity \<10 IU/dL).
15. Receives regular VWF concentrate (at least 1/week) as part of their routine care (usual dose ≤50 IU/kg).

Key Exclusion Criteria:

1. Personal history of venous or arterial thrombosis or thromboembolic disease, except for catheter-associated, superficial venous thrombosis.
2. High risk thrombophilia: Homozygous Factor V Leiden (FVL), compound heterozygous FVL/Prothrombin gene mutation, Antithrombin deficiency with activity \<50%. Congenital Protein C and Protein S deficiency with levels \<50%.
3. Body mass index (BMI) \>35 kg/m\^2 (obese, adjusted for ethnicity).
4. Presence of other conditions that substantially increase risk of thrombosis either individually (for participants \>65 years of age) or in combination (for participants ≤65 years of age), at the discretion of the Investigator or Medical Monitor.
5. Clinically significant cardiovascular disease.
6. Other known severe bleeding disorder(s) other than VWD.
7. Requirement for concomitant medications that affect hemostasis (including, but not limited to anticoagulation, antiplatelet agents, certain non-steroidal anti-inflammatory drugs) and cannot refrain from use for 14 days prior to the first dose of study drug and throughout the study.

   Exclusion Criteria for Part A and Part B Only
8. Requirement for ongoing hemostatic treatment to prevent bleeding (bleed prophylaxis). Prophylaxis administered intermittently for procedures or surgery to reduce bleeding risk is permitted.

Where it's running

• Innovative Hematology, Inc./Indiana Hemophilia and Thrombosis Center
  Indianapolis, Indiana, United States Recruiting
• Royal Prince Alfred Hospital
  Camperdown, Sydney, Australia Recruiting
• The Alfred Hospital
  Melbourne, Victoria, Australia Recruiting
• Basingstoke and North Hampshire Hospital
  Basingstoke, Hampshire, United Kingdom Recruiting
• University Hospital of Wales
  Cardiff, United Kingdom Recruiting
• Richmond Pharmacology
  London, United Kingdom Recruiting

Study contacts

• Study coordinator: Clinical Trials
• Email: clinicaltrials@hemab.com
• Phone: 080 8304 6409

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Understanding bleeding and treatment in Von Willebrand Disease

  This study is trying to learn more about bleeding and treatment experiences in people with Von Willebrand Disease, especially those with Type 1, to help improve future care.

  Recruiting at 17 sites Hemab ApS · Phoenix, Arizona and 16 other locations · NCT06610201

• SR604 in Von Willebrand Disease: a Phase II study to see if it helps with bleeding

  This Phase 2 trial tests SR604 in adults with von Willebrand disease to see if it can improve bleeding control and how the drug behaves in the body.

  Recruiting at 9 sites Phase 2 Shanghai RAAS Blood Products Co., Ltd. · Changsha and 8 other locations · NCT07640893

• ALN-6400 for women with von Willebrand disease and heavy menstrual bleeding

  This study tests ALN-6400 to see if it can help reduce heavy menstrual bleeding in adult and adolescent women with von Willebrand disease.

  Recruiting Phase 2 Alnylam Pharmaceuticals · Orange, California and 20 other locations · NCT07575308

• Vonicog alfa (rVWF) use in children with von Willebrand disease

  This observational program will see how vonicog alfa (rVWF) works and whether it causes side effects in children with von Willebrand disease in Japan.

  Recruiting Takeda · Tokyo, Tokyo · NCT07404644

• Endothelial colony-forming cell behavior in people with von Willebrand disease and acquired von Willebrand syndrome

  This project will see how endothelial colony-forming cells (ECFCs) behave in people with VWD or AVWS compared with healthy volunteers.

  Recruiting Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico · Milan · NCT07358013

• BT200 (Rondaptivon Pegol) for people with type 2B von Willebrand disease and low platelets

  This trial will test whether BT200 (Rondaptivon Pegol) can raise von Willebrand factor, platelet count, and factor VIII and reduce bleeding in adults with type 2B VWD who have low platelets.

  Recruiting Phase 2 Medical University of Vienna · Vienna, State of Vienna · NCT07273721

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.